Conatus Pharmaceuticals' (CNAT) Price Target Raised to $26 at SunTrust
Tweet
Share
E-mail
Get Alerts CNAT Hot Sheet
Price: $0.56 --0%
Rating Summary:
3 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 13 | New: 70
Rating Summary:
3 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 13 | New: 70
Join SI Premium – FREE
SunTrust Robinson Humphrey maintained a Buy rating on Conatus Pharmaceuticals (NASDAQ: CNAT) and raised its price target to $26.00 (from $17.00).
For an analyst ratings summary and ratings history on Conatus Pharmaceuticals click here. For more ratings news on Conatus Pharmaceuticals click here.
Shares of Conatus Pharmaceuticals closed at $1.96 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HSBC Upgrades TotalEnergies SE (TTE:FP) (TTE) to Buy
- Repsol SA (REP:SM) (REPYY) PT Raised to EUR37 at HSBC
- Chevron (CVX) PT Raised to $250 at HSBC
Create E-mail Alert Related Categories
Analyst PT Change, Momentum MoversRelated Entities
SunTrust Robinson HumphreySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
